Inventor · disambiguated record
Erik Fenster
Also filed as: FENSTER ERIK
29 granted patents·2 pending applications·124 citations·filing 2012–2023
96Inventor score
Top patents by PatentIndex Score
31 records- 0198US8691868B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2012·Granted Apr 8, 2014·57 cites·31 claims
- 0292US8901169B2Neprilysin inhibitorsFENSTER ERIK·Filed 2014·Granted Dec 2, 2014·14 cites·31 claims
- 0391US9533962B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 3, 2017·6 cites·28 claims
- 0490US10744104B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 18, 2020·2 cites·20 claims
- 0589US9872855B2(2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jan 23, 2018·5 cites·9 claims
- 0688US12016835B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Jun 25, 2024·0 cites·16 claims
- 0788US11033533B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jun 15, 2021·1 cites·20 claims
- 0888US9682052B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2015·Granted Jun 20, 2017·4 cites·37 claims
- 0987US10538513B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Jan 21, 2020·4 cites·16 claims
- 1087US10172834B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 8, 2019·3 cites·3 claims
- 1187US10123984B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Nov 13, 2018·3 cites·10 claims
- 1286US9150500B2Neprilysin inhibitorsHUGHES ADAM D·Filed 2014·Granted Oct 6, 2015·5 cites·32 claims
- 1385US10392368B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 27, 2019·5 cites·46 claims
- 1484US11590116B2Substituted pyridines and methods of useTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Feb 28, 2023·1 cites·25 claims
- 1584US10548879B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 4, 2020·2 cites·20 claims
- 1684US9428457B2Neprilysin inhibitorsFENSTER ERIK·Filed 2015·Granted Aug 30, 2016·3 cites·4 claims
- 1784US9096496B2Neprilysin inhibitorsFENSTER ERIK·Filed 2014·Granted Aug 4, 2015·4 cites·10 claims
- 1883US10968205B2Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Apr 6, 2021·1 cites·26 claims
- 1983US9688616B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jun 27, 2017·2 cites·5 claims
- 2080US10851102B2Imidazole and triazole containing bicyclic compounds as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Dec 1, 2020·1 cites·19 claims
- 2179US11642332B2(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted May 9, 2023·0 cites·20 claims
- 2279US9840460B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Dec 12, 2017·1 cites·5 claims
- 2376US11547687B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jan 10, 2023·0 cites·20 claims
- 2470US2022119369A1Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Application pending·0 cites
- 2570US2023218597A1Substituted pyridines and methods of useTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Application pending·0 cites
- 2666US10053417B2Neprilysin inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Aug 21, 2018·0 cites·5 claims
- 2760US11339160B2Imidazole and triazole containing bicyclic compounds as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted May 24, 2022·0 cites·17 claims
- 2860US9868698B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Jan 16, 2018·0 cites·2 claims
- 2957US9433598B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Sep 6, 2016·0 cites·26 claims
- 3056US9670143B2(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acidTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Jun 6, 2017·0 cites·2 claims
- 3149US11697648B2Fused pyrimidine pyridinone compounds as JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jul 11, 2023·0 cites·22 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →